SFI
UTHR icon

Susquehanna Fundamental Investments’s United Therapeutics UTHR Stock Holding History

Susquehanna Fundamental Investments’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-18,696
Closed -$5.76M – 1017
2025
Q1 		$5.76M Sell
18,696
-31,839
-63% -$10.9M 0.08% 293
2024
Q4 		$17.8M Buy
+50,535
New +$18.6M 0.25% 91
2024
Q2 		$17.3M Sell
54,235
-470
-0.9% -$124K 0.4% 69
2024
Q1 		$12.6M Buy
+54,705
New +$12.3M 0.59% 43
2023
Q2 		– Sell
-15,005
Closed -$3.36M – 878
2023
Q1 		$3.36M Sell
15,005
-11,475
-43% -$2.83M 0.08% 274
2022
Q4 		$7.36M Buy
26,480
+459
+2% +$116K 0.13% 219
2022
Q3 		$5.45M Buy
+26,021
New +$5.82M 0.09% 304
2022
Q1 		$2.06M Buy
+11,475
New +$2.19M 0.04% 571

Other funds holding UTHR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Susquehanna Fundamental Investments's UTHR Position: Q2 2025 in Review

Susquehanna Fundamental Investments sold out of United Therapeutics (UTHR) in Q2 2025, closing a stake of 18,696 shares — an estimated $5.76M sold.

Susquehanna Fundamental Investments first reported a position in UTHR in Q1 2022 and held it in 8 quarters. The position peaked at $17.8M in Q4 2024. 670 funds tracked by Wall St. Rank hold UTHR as of Q2 2025.

  • Susquehanna Fundamental Investments reported no remaining United Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Susquehanna Fundamental Investments sold 18,696 United Therapeutics shares in Q2 2025, an estimated $5.76M.
  • Susquehanna Fundamental Investments first reported a position in United Therapeutics in Q1 2022 and held it in 8 quarters.
  • Susquehanna Fundamental Investments's United Therapeutics position peaked at $17.8M in Q4 2024.
  • 670 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2025.

Based on Susquehanna Fundamental Investments's 13F filing for Q2 2025, filed 14 Aug 2025.